Pharsight

1. Firvanq Kit patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688046	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959946	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959948	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959949	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10493028	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US10959947	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)
US11638692	AZURITY	Composition and method for vancomycin oral liquid	Mar, 2035 (10 years from now)

Market Authorisation Date: 26 January, 2018

Treatment: Treatment of c. difficile-associated diarrhea; Treatment of staphylococcal enterocolitis

Dosage: FOR SOLUTION;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
25 mg/mL and 50 mg/mL	18 May, 2020	1	14 Nov, 2022	13 Mar, 2035	Eligible

Strength	Dosage	Availability
EQ 25MG BASE/ML	FOR SOLUTION;ORAL	Prescription
EQ 50MG BASE/ML	FOR SOLUTION;ORAL	Prescription

Application	Filing Date	Opposition Party	Legal Status

EP15791287A	2020-10-01	df-mp Dörries Frank-Molnia & Pohlman Patentanwälte Rechtsanwälte ParG mbB	Revoked

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188697	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (11 years from now)
US11517609	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (11 years from now)
US10039804	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (11 years from now)
US10849956	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (11 years from now)
US11628200	XELLIA PHARMS APS	Glycopeptide compositions	Nov, 2035 (11 years from now)

Market Authorisation Date: 15 February, 2019

Treatment: Method of treating bacterial infections

Dosage: SOLUTION;INTRAVENOUS